Cargando…

Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis- related graft failure and disseminated bacillus Calmette-Guérin infection

Detalles Bibliográficos
Autores principales:	Tucci, Francesca, Gallo, Vera, Barzaghi, Federica, Ferrua, Francesca, Migliavacca, Maddalena, Calbi, Valeria, Doglio, Matteo, Fratini, Elena Sophia, Karakas, Zeynep, Guner, Sukru, Zambelli, Matilde, Parisi, Cristina, Milani, Raffaella, Gattillo, Salvatore, Mazzi, Benedetta, Oltolini, Chiara, Barbera, Maurizio, Baldoli, Cristina, Cirillo, Daniela Maria, Asnaghi, Veronica, de Min, Cristina, Cicalese, Maria Pia, Ciceri, Fabio, Aiuti, Alessandro, Bernardo, Maria Ester
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849754/ https://www.ncbi.nlm.nih.gov/pubmed/32817285 http://dx.doi.org/10.3324/haematol.2020.255620

Ejemplares similares

Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series
por: Canarutto, Daniele, et al.
Publicado: (2023)

Hemophagocytic inflammatory syndrome in ADA-SCID: report of two cases and literature review
por: Fratini, Elena Sophia, et al.
Publicado: (2023)

Peripheral blood stem and progenitor cell collection in pediatric candidates for ex vivo gene therapy: a 10-year series
por: Canarutto, Daniele, et al.
Publicado: (2021)

Efficacy and safety of emapalumab in macrophage activation syndrome
por: De Benedetti, Fabrizio, et al.
Publicado: (2023)

Wiskott–Aldrich syndrome: Oral findings and microbiota in children and review of the literature
por: Lucchese, Alessandra, et al.
Publicado: (2022)

A Novel Assay in Whole Blood Demonstrates Restoration of Mitochondrial Activity in Phagocytes After Successful HSCT in Hyperinflamed X-Linked Chronic Granulomatous Disease
por: Migliavacca, Maddalena, et al.
Publicado: (2022)

Third cranial nerve palsy in an 88-year-old man after SARS-CoV-2 mRNA vaccination: change of injection site and type of vaccine resulted in an uneventful second dose with humoral immune response
por: Cicalese, Maria Pia, et al.
Publicado: (2022)

Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID
por: Stirnadel-Farrant, Heide, et al.
Publicado: (2018)

Use of Defibrotide to help prevent post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic stem cell gene therapy
por: Calbi, Valeria, et al.
Publicado: (2018)

Alterations in the brain adenosine metabolism cause behavioral and neurological impairment in ADA-deficient mice and patients
por: Sauer, Aisha V., et al.
Publicado: (2017)

Bone marrow harvesting from paediatric patients undergoing haematopoietic stem cell gene therapy
por: Tucci, Francesca, et al.
Publicado: (2019)

A Case of Two Adult Brothers with Wiskott-Aldrich Syndrome, One Treated with Gene Therapy and One with HLA-Identical Hematopoietic Stem Cell Transplantation
por: Consiglieri, Giulia, et al.
Publicado: (2021)

First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature
por: Migliavacca, Maddalena, et al.
Publicado: (2018)

Gene therapy for ADA‐SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products
por: Aiuti, Alessandro, et al.
Publicado: (2017)

Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis
por: Tucci, Francesca, et al.
Publicado: (2018)

Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report
por: Cenciarelli, Sabina, et al.
Publicado: (2020)

Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach
por: Jacqmin, Philippe, et al.
Publicado: (2021)

Case Report: Consistent disease manifestations with a staggered time course in two identical twins affected by adenosine deaminase 2 deficiency
por: Barzaghi, Federica, et al.
Publicado: (2022)

Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access
por: Fumagalli, Francesca, et al.
Publicado: (2022)

Pioglitazone as a novel therapeutic approach in chronic granulomatous disease
por: Migliavacca, Maddalena, et al.
Publicado: (2016)

Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL)
por: Merli, Pietro, et al.
Publicado: (2020)

Maternal T-cell engraftment impedes with diagnosis of a SCID-ADA patient
por: Lanfranchi, Arnalda, et al.
Publicado: (2018)

Evaluation of clonal hematopoiesis in pediatric ADA-SCID gene therapy participants
por: White, Shanna L., et al.
Publicado: (2022)

ALPS-Like Phenotype Caused by ADA2 Deficiency Rescued by Allogeneic Hematopoietic Stem Cell Transplantation
por: Barzaghi, Federica, et al.
Publicado: (2019)

Nonconditioned ADA-SCID gene therapy reveals ADA requirement in the hematopoietic system and clonal dominance of vector-marked clones
por: Uchiyama, Toru, et al.
Publicado: (2021)

Review of Treatment for Adenosine Deaminase Deficiency (ADA) Severe Combined Immunodeficiency (SCID)
por: Secord, Elizabeth, et al.
Publicado: (2022)

Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients
por: Schuelke, Matthew R., et al.
Publicado: (2023)

Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study
por: Ferrua, Francesca, et al.
Publicado: (2019)

Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID)
por: Booth, Claire, et al.
Publicado: (2009)

Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
por: Moretti, Federico A., et al.
Publicado: (2021)

PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID
por: Dorsey, Morna J., et al.
Publicado: (2023)

A novel genomic inversion in Wiskott-Aldrich–associated autoinflammation
por: Brigida, Immacolata, et al.
Publicado: (2016)

Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety
por: Cicalese, Maria Pia, et al.
Publicado: (2018)

Correction to: PEGylated Recombinant Adenosine Deaminase Maintains Detoxification and Lymphocyte Counts in Patients with ADA-SCID
por: Dorsey, Morna J., et al.
Publicado: (2023)

Gene therapy for lysosomal storage disorders: recent advances for metachromatic leukodystrophy and mucopolysaccaridosis I
por: Penati, Rachele, et al.
Publicado: (2017)

Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy
por: Igarashi, Yuka, et al.
Publicado: (2017)

Author Correction: Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy
por: Moretti, Federico A., et al.
Publicado: (2021)

JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long‐known gene
por: Di Matteo, Gigliola, et al.
Publicado: (2018)

In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution Phases
por: Biasco, Luca, et al.
Publicado: (2016)

S106: LONG-TERM FOLLOW-UP OF BETA-THALASSEMIA PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL GENE THERAPY
por: Marktel, S, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_04c9grstb1tg82teh8n6mfvel5